参考文献/References:
[1].International Diabetes Federation. IDF Diabetes Atlas,9th edn[R]. Brussels,Belgium:2019.Available at: https://www.diabetesatlas.org.
[2].DeFronzo RA,Ferrannini E,Groop L,et al. Type 2 diabetes mellitus[J]. Nat Rev Dis Primers,2015,1:15019.
[3].Chatterjee S,Khunti K,Davies MJ. Type 2 diabetes[J]. Lancet,2017,389(10085):2239-2251.
[4].Johansen OE,Birkeland KI. Preventing macrovascular disease in patients with type 2 diabetes mellitus[J]. Am J Cardiovasc Drugs,2003,3(4):283-297.
[5].Pang M,Li Y,Gu W,et al. Recent advances in epigenetics of macrovascular complications in diabetes mellitus[J]. Heart Lung Circ,2021,30(2):186-196.
[6].蒋飞霞,苏宏业,黄济华. 2型糖尿病大血管并发症的防治进展[J]. 中国现代医生,2018,56(22):156-160.
[7].葛学民. 糖尿病微血管并发症[J]. 中国社区医师,2019,35(4):12,14.
[8].李琳. 北京社区人群残粒胆固醇水平与心血管事件发生风险的回顾性队列研究[D]. 中国人民解放军医学院,2019.
[9].陈培豪,高山. 缺血性卒中的分型——从原始TOAST到ASCO分型[J]. 中国卒中杂志,2011,6(5):416-422.
[10].张磊. 彩色多普勒超声在糖尿病患者下肢血管病变的诊断价值[J]. 影像研究与医学应用,2020,4(24):129-130.
[11].朱宇莉,丁红. 超声无创评价早期动脉粥样硬化的研究进展[J]. 中国医学影像学杂志,2014,22(7):554-556.
[12].王明月,勇强. DSA、MRA、MS-CT及血流剪切力等影像学检查方法在评价颈动脉粥样硬化斑块形成及易损性的诊断价值[J]. 血管与腔内血管外科杂志,2018,4(2):147-156.
[13].Pan FS,Xu M,Yu L,et al. Relationship between carotid intima-media thickness and carotid artery stiffness assessed by ultrafast ultrasound imaging in patients with type 2 diabetes[J]. Eur J Radiol,2019,111:34-40.
[14].Syed MB,Fletcher AJ,Forsythe RO,et al. Emerging techniques in atherosclerosis imaging[J]. Br J Radiol,2019,92(1103):20180309.
[15].胡莉君,余晓梅. 超声弹性成像评价2型糖尿病合并高血压患者动脉血管壁弹性的临床研究[J]. 医疗卫生装备,2013,34(7):67-68,86.
[16].张丽,王芳. 高频超声在糖尿病颈动脉血管粥样硬化斑块诊断中的应用效果研究[J]. 影像研究与医学应用,2022,6(5):29-31.
[17].马奕宁. 糖尿病对脑梗死患者头颈动脉多层螺旋CT血管成像特征研究[J]. 实用糖尿病杂志,2020,16(3):37-38.
[18].张保朋,王道清,程留慧,等. 双源CT评价糖尿病患者颈动脉斑块与脑梗死的关系[J]. 中国实用神经疾病杂志,2016,19(10):29-30.
[19].Heinsen LJ,Pararajasingam G,Andersen TR,et al. High-risk coronary artery plaque in asymptomatic patients with type 2 diabetes:clinical risk factors and coronary artery calcium score[J]. Cardiovasc Diabetol,2021,20(1):164.
[20].Tesche C,Baquet M,Bauer MJ,et al. Prognostic utility of coronary computed tomography angiography-derived plaque information on long-term outcome in patients with and without diabetes mellitus[J]. J Thorac Imaging,2021.doi:10.1097/RTI.0000000000000626.Online ahead of print.
[21].Shi R,Shi K,Yang ZG,et al. Serial coronary computed tomography angiography-verified coronary plaque progression:comparison of stented patients with or without diabetes[J]. Cardiovasc Diabetol,2019,18(1):123.
[22].刘海深. MRI血管成像在糖尿病并发血管疾病诊断及治疗中的应用[J]. 慢性病学杂志,2020,21(9):1414-1415,1418.
[23].Hatsukami TS,Ross R,Polissar NL,et al. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging[J]. Circulation,2000,102(9):959-964.
[24].Kerwin WS,Zhao X,Yuan C,et al. Contrast-enhanced MRI of carotid atherosclerosis:dependence on contrast agent[J]. J Magn Reson Imaging,2009,30(1):35-40.
[25].Chu B,Kampschulte A,Ferguson MS,et al. Hemorrhage in the atherosclerotic carotid plaque:a high-resolution MRI study[J]. Stroke,2004,35(5):1079-1084.
[26].Gao X,Song J,Watase H,et al. Differences in carotid plaques between symptomatic patients with and without diabetes mellitus[J]. Arterioscler Thromb Vasc Biol,2019,39(6):1234-1239.
[27].R?hrl B,Kunz RP,Oberholzer K,et al. Gadofosveset-enhanced MR angiography of the pedal arteries in patients with diabetes mellitus and comparison with selective intraarterial DSA[J]. Eur Radiol,2009,19(12):2993-3001.
[28].卢武胜. 糖尿病下肢血管病变的影像学检查和介入治疗[D]. 首届四川东北部介入放射学学术年会,2007.
[29].Huang D,Swanson EA,Lin CP,et al. Optical coherence tomography[J]. Science,1991,254(5035):1178-1181.
[30].Munk MR,Giannakaki-Zimmermann H,Berger L,et al. OCT-angiography:a qualitative and quantitative comparison of 4 OCT-A devices[J]. PLoS One ,2017,12(5):e0177059.
[31].王贺,陈臻. 光学相干断层扫描血管成像术在糖尿病性视网膜病变中的应用[J]. 中国医疗设备,2021,36(1):167-170.
[32].李小豪,张丽,孙婷婷,等. 光学相干断层扫描血管成像在糖尿病微血管病变中的应用[J]. 国际眼科杂志,2020,20(10):1756-1759.
[33].张仙玉,毛敏,左中. PET/CT对冠心病易损斑块和存活心肌的早期识别价值[J]. 心血管病学进展,2021,42(9):816-819.
[34].陆国秀,郝珊瑚,王治国,等. 18F-FDG、18F-NaF PET/CT及心脏CT血管成像联合显像对2型糖尿病冠状动脉疾病的诊断及评估[J]. 中国医科大学学报,2020,49(11):1002-1006.
[35].Figueroa AL,Abdelbaky A,Truong QA,et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events[J]. JACC Cardiovasc Imaging,2013,6(12):1250-1259.
[36].Tarkin JM,Dweck MR,Evans NR,et al. Imaging Atherosclerosis[J]. Circ Res,2016,118(4):750-769.
[37].de Boer SA,Hovinga-de Boer MC,Heerspink HJ,et al. Arterial stiffness is positively associated with 18F-fluorodeoxyglucose positron emission tomography-assessed subclinical vascular inflammation in people with early type 2 diabetes[J]. Diabetes Care,2016,39(8):1440-1447.
[38].Bernelot Moens SJ,Stoekenbroek RM,van der Valk FM,et al. Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes:a cross-sectional study[J]. BMC Cardiovasc Disord,2016,16(1):237.
[39].Jensen JK,Zobel EH,von Scholten BJ,et al. Effect of 26 weeks of liraglutide treatment on coronary artery inflammation in type 2 diabetes quantified by [64Cu]Cu-DOTATATE PET/CT:results from the LIRAFLAME trial[J]. Front Endocrinol(Lausanne),2021,12:790405.
[40].Chen Y,Huang D,Liu J,et al. Non-invasive detection of fetal vascular endothelial function in gestational diabetes mellitus[J]. Front Endocrinol(Lausanne),2021,12:763683.
[41].Schick F,Ripa RS,Hansen TW,et al. Editorial:advanced cardiovascular imaging in diabetes[J]. Front Endocrinol(Lausanne),2022,13:848975.
相似文献/References:
[1]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(11):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[2]李嘉仪 黄龙祥 罗素新.钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
LI JiayiHUANG LongxiangLUO Suxin.SGLT-2 Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
[3]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(11):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[4]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[5]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(11):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[6]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(11):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[7]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(11):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[8]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(11):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[9]吴易航 张宇辉 张健.SGLT2 i恩格列净对2型糖尿病患者心脏保护作用的研究进展[J].心血管病学进展,2020,(8):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
WU Yihang,ZHANG Yuhui,ZHANG Jian.Progresses on the Cardiovascular Protection of SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(11):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
[10]张欣 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂相关心血管益处的可能潜在机制[J].心血管病学进展,2020,(9):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
ZHANG Xin,GUO Yifang.Potential Mechanisms of Sodium-glucose Co-transporter 2 Inhibitor-related Cardiovascular Benefits[J].Advances in Cardiovascular Diseases,2020,(11):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
[11]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(11):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]